QURE Share Price Performance
US$23.93
8.46 (54.69%)
56.8% undervalued intrinsic discount
US$55.44
Fair Value
Price US$23.93
AnalystConsensusTarget US$55.44
AnalystLowTarget US$33.36
Fair ValueUS$55.44
Share Pricen/a
uniQure N.V. Stock Price
- 2 Narratives written by author
- 1 Comments on narratives written by author
- 26 Fair Values set on narratives written by author
QURE Community Narratives
AN
Fair Value US$55.44 56.8% undervalued intrinsic discount
QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake
1users have liked this narrative
1users have commented on this narrative
9users have followed this narrative
AN
Fair Value US$33.36 28.3% undervalued intrinsic discount
Tighter Gene Therapy Regulations And Safety Risks Will Challenge Neurology Pipeline Yet Offer Long-Term Promise
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake
Key Takeaways Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment. Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.Read more
395
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
9users have followed this narrative
AN
US$55.44
56.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
158.12% p.a.
Profit Margin
16.03%
Future PE
120.01x
Price in 2028
US$68.28
Tighter Gene Therapy Regulations And Safety Risks Will Challenge Neurology Pipeline Yet Offer Long-Term Promise
Catalysts About uniQure uniQure develops gene therapies targeting severe neurological and metabolic rare diseases. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$33.36
28.3% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
37.54% p.a.
Profit Margin
16.03%
Future PE
479.71x
Price in 2028
US$41.29
Trending Discussion
Recently Updated Narratives
AN
QURE: Future Regulatory Clarity Will Drive Gene Therapy Upside Despite FDA Setback
Fair Value: US$55.44 56.8% undervalued intrinsic discount
9 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Tighter Gene Therapy Regulations And Safety Risks Will Challenge Neurology Pipeline Yet Offer Long-Term Promise
Fair Value: US$33.36 28.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
uniQure N.V. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -3.77
- -781.86%
- -1,492.90%
- 226.2%
About QURE
- Founded
- 1998
- Employees
- 209
- CEO
- WebsiteView website
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
